Drug companies lose hundreds of millions of dollars when large-scale human clinical trials fail. Helen Pearson examines whether alternative procedures could help avoid such disappointments. Cape Town in October has many attractions: balmy temperatures, enticing beaches, ample wines and the indomitable presence of Table Mountain. But for the many neurologists attending the Joint World Congress on Stroke there late last month, it was a glum place to be.
展开▼
